START-UP’s 2012 Medical Device Census

Our data-driven review of the portfolios of more than two dozen leading medical device VCs show that the median life span of venture-backed companies hovers at seven years. Younger medtech companies are getting by – and getting farther in the regulatory process – with less capital, reflecting the current state of an industry that sees a whole lot of belt tightening in its future.

In what is arguably Kevin Costner’s finest film role, the actor plays journeyman minor league catcher Crash Davis in Bull Durham, who laments the razor’s edge difference between his long, but undistinguished, career and those players who “make it to the show.” A drunken and forlorn Davis notes that one base hit a week over the span of a season – a dying quail, a ground ball with eyes – is the difference between playing in the Carolina League and Yankee Stadium. The scene represents why baseball is an apt metaphor for life – and for the venture capital business. In the case of the latter, the only difference between a top-tier firm and a mid-tier firm is the one or two base hits (read: exits) a year that can raise an IRR high enough to keep a venture firm in the majors (and, these days, in business).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America